Metastatic melanoma: is biochemotherapy the future? (Q36167483)

12 August 2017

1 reference

title

Metastatic melanoma: is biochemotherapy the future? (English)

1 reference

12 August 2017

1 reference

3

Peter H Wiernik

1 reference

12 August 2017

2

Janice P Dutcher

1 reference

12 August 2017

Doru T Alexandrescu

1

1 reference

12 August 2017

publication date

1 January 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

22

1 reference

12 August 2017

issue

2

1 reference

12 August 2017

page(s)

101-111

1 reference

https://scigraph.springernature.com/pub.10.1385/mo:22:2:101

12 August 2017

exact match

0 references

cites work

Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma

1 reference

12 December 2020

Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)

1 reference

12 December 2020

Immunotherapy of C3H/HeJ mammary adenocarcinoma with interleukin-2, mistletoe lectin or their combination. effects on tumour growth, capillary leakage and nitric oxide (NO) production

1 reference

12 December 2020

Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study

1 reference

12 December 2020

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b

1 reference

12 December 2020

Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin-2, and interferon-alpha

1 reference

12 December 2020

A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma

1 reference

12 December 2020

GM-CSF with biochemotherapy (cisplatin, DTIC, tamoxifen, IL-2 and interferon-alpha): a phase I trial in melanoma

1 reference

12 December 2020

Nitric oxide and T helper cell immunity

1 reference

12 December 2020

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

1 reference

12 December 2020

Nitric oxide/nucleophile complexes inhibit the in vitro proliferation of A375 melanoma cells via nitric oxide release.

1 reference

12 December 2020

Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma

1 reference

12 December 2020

Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma

1 reference

12 December 2020

Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma

1 reference

12 December 2020

Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.

1 reference

12 December 2020

Sequential chemoimmunotherapy in the treatment of metastatic melanoma

1 reference

12 December 2020

Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.

1 reference

12 December 2020

A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.

1 reference

12 December 2020

Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial

1 reference

12 December 2020

Interleukin-2 with and without LAK cells in metastatic renal cell carcinoma: the Lyon first-year experience in 20 patients

1 reference

12 December 2020

Interleukin-2 plus chemotherapy for patients with metastatic melanoma

1 reference

12 December 2020

Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen

1 reference

12 December 2020

Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Gr

1 reference

12 December 2020

A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.

1 reference

12 December 2020

Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma

1 reference

12 December 2020

Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study

1 reference

12 December 2020

Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy

1 reference

12 December 2020

A multicenter phase II clinical trial using dacarbazine and continuous infusion interleukin-2 for metastatic melanoma. Clinical data and immunomonitoring

1 reference

12 December 2020

Long-term outcome of treatment with dacarbazine, cisplatin, interferon-alpha and intravenous high dose interleukin-2 in poor risk melanoma patients.

1 reference

12 December 2020

A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanoma

1 reference

12 December 2020

Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials

1 reference

12 December 2020

Nitric oxide induces BNIP3 expression that causes cell death in macrophages

1 reference

12 December 2020

Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma

1 reference

12 December 2020

Outpatient combination chemoimmunotherapy for patients with metastatic melanoma. Results of a phase I/II trial

1 reference

12 December 2020

Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha

1 reference

12 December 2020

Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma

1 reference

12 December 2020

Salpêtrière Hospital experience with biochemotherapy in metastatic melanoma.

1 reference

12 December 2020

Flavone acetic acid (FAA) with recombinant interleukin-2 (TIL-2) in advanced malignant melanoma. II: Induction of nitric oxide production

1 reference

12 December 2020

A randomised trial of vindesine plus interferon-alpha 2b compared with interferon-alpha 2b or vindesine alone in the treatment of advanced malignant melanoma

1 reference

12 December 2020

Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group

1 reference

12 December 2020

Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM)

1 reference

12 December 2020

Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma

1 reference

12 December 2020

Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma.

1 reference

12 December 2020

Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.

1 reference

12 December 2020

Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group

1 reference

12 December 2020

A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma

1 reference

12 December 2020

Nitric oxide as a regulatory and effector molecule in the immune system.

1 reference

12 December 2020

Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy

1 reference

12 December 2020

Biochemotherapy for metastatic melanoma with limited central nervous system involvement

1 reference

12 December 2020

Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial.

1 reference

12 December 2020

Identifiers

DOI

10.1385/MO:22:2:101

1 reference

Dimensions Publication ID

12 August 2017

1020377939

0 references

1 reference